Literature DB >> 21497288

Nested high-resolution melting curve analysis a highly sensitive, reliable, and simple method for detection of JAK2 exon 12 mutations--clinical relevance in the monitoring of polycythemia.

Serge Carillo1, Laurent Henry, Eric Lippert, François Girodon, Isabelle Guiraud, Céline Richard, Frédérique Dubois Galopin, Cedric Cleyrat, Eric Jourdan, Robert Kralovics, Sylvie Hermouet, Thierry Lavabre-Bertrand.   

Abstract

JAK2 exon 12 mutations are found in myeloproliferative disorders characterized by erythrocytosis. Lying in a 33-bp region and conserving the open reading frame, they often present a low allelic burden (<10%), which excludes screening with techniques such as allele-specific PCR or different sequencing protocols. High-resolution melting (HRM), a fast in-tube method, seems the most accurate routine technique for that. We describe a reliable and powerful nested HRM technique, independent of DNA preparation and with technical sensitivity of 100% (95% CI, 93% to 100%) and specificity of 96.7% (95% CI, 89.7% to 96.7%). Screening a cohort of 10 idiopathic erythrocytosis, 28 polycythemia vera, and 7 secondary erythrocytosis cases allowed the detection of 15 mutants, including 9 different mutations, of which 3 were unreported, all in the polycythemia vera group, and presented a characteristic profile: pure erythrocytosis associated with low serum erythropoietin. Threshold detection level ranged from 1% to 3% allelic burden, depending on the mutation. All of the HRM positive signals were found mutated by sequencing. Six of them (40%), however, required cloning before sequencing, because of low allelic burden. Classic techniques such as genomic sequencing may therefore miss patients with mutations. Given its sensitivity, HRM (and nested HRM) can be used in routine diagnosis and seems to be the most efficient of current techniques for detection of JAK2 exon 12 mutations.
Copyright © 2011 American Society for Investigative Pathology and the Association for Molecular Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21497288      PMCID: PMC3077738          DOI: 10.1016/j.jmoldx.2010.12.002

Source DB:  PubMed          Journal:  J Mol Diagn        ISSN: 1525-1578            Impact factor:   5.568


  20 in total

1.  Quantitative heteroduplex analysis for single nucleotide polymorphism genotyping.

Authors:  Robert A Palais; Michael A Liew; Carl T Wittwer
Journal:  Anal Biochem       Date:  2005-08-31       Impact factor: 3.365

2.  The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera.

Authors:  Eric Lippert; Marjorie Boissinot; Robert Kralovics; François Girodon; Irène Dobo; Vincent Praloran; Nathalie Boiret-Dupré; Radek C Skoda; Sylvie Hermouet
Journal:  Blood       Date:  2006-05-25       Impact factor: 22.113

3.  Prevalance of JAK2 V617F and exon 12 mutations in polycythaemia vera.

Authors:  Linda M Scott; Philip A Beer; Anthony J Bench; Wendy N Erber; Anthony R Green
Journal:  Br J Haematol       Date:  2007-11       Impact factor: 6.998

4.  Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera.

Authors:  A Pardanani; T L Lasho; C Finke; C A Hanson; A Tefferi
Journal:  Leukemia       Date:  2007-06-28       Impact factor: 11.528

5.  A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.

Authors:  Chloé James; Valérie Ugo; Jean-Pierre Le Couédic; Judith Staerk; François Delhommeau; Catherine Lacout; Loïc Garçon; Hana Raslova; Roland Berger; Annelise Bennaceur-Griscelli; Jean Luc Villeval; Stefan N Constantinescu; Nicole Casadevall; William Vainchenker
Journal:  Nature       Date:  2005-04-28       Impact factor: 49.962

6.  Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.

Authors:  Ross L Levine; Martha Wadleigh; Jan Cools; Benjamin L Ebert; Gerlinde Wernig; Brian J P Huntly; Titus J Boggon; Iwona Wlodarska; Jennifer J Clark; Sandra Moore; Jennifer Adelsperger; Sumin Koo; Jeffrey C Lee; Stacey Gabriel; Thomas Mercher; Alan D'Andrea; Stefan Fröhling; Konstanze Döhner; Peter Marynen; Peter Vandenberghe; Ruben A Mesa; Ayalew Tefferi; James D Griffin; Michael J Eck; William R Sellers; Matthew Meyerson; Todd R Golub; Stephanie J Lee; D Gary Gilliland
Journal:  Cancer Cell       Date:  2005-04       Impact factor: 31.743

7.  Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.

Authors:  E Joanna Baxter; Linda M Scott; Peter J Campbell; Clare East; Nasios Fourouclas; Soheila Swanton; George S Vassiliou; Anthony J Bench; Elaine M Boyd; Natasha Curtin; Mike A Scott; Wendy N Erber; Anthony R Green
Journal:  Lancet       Date:  2005 Mar 19-25       Impact factor: 79.321

8.  A gain-of-function mutation of JAK2 in myeloproliferative disorders.

Authors:  Robert Kralovics; Francesco Passamonti; Andreas S Buser; Soon-Siong Teo; Ralph Tiedt; Jakob R Passweg; Andre Tichelli; Mario Cazzola; Radek C Skoda
Journal:  N Engl J Med       Date:  2005-04-28       Impact factor: 91.245

9.  The frequency of JAK2 exon 12 mutations in idiopathic erythrocytosis patients with low serum erythropoietin levels.

Authors:  Melanie J Percy; Linda M Scott; Wendy N Erber; Claire N Harrison; John T Reilly; Frank G C Jones; Anthony R Green; Mary Frances McMullin
Journal:  Haematologica       Date:  2007-12       Impact factor: 9.941

10.  JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis.

Authors:  Linda M Scott; Wei Tong; Ross L Levine; Mike A Scott; Philip A Beer; Michael R Stratton; P Andrew Futreal; Wendy N Erber; Mary Frances McMullin; Claire N Harrison; Alan J Warren; D Gary Gilliland; Harvey F Lodish; Anthony R Green
Journal:  N Engl J Med       Date:  2007-02-01       Impact factor: 91.245

View more
  11 in total

1.  Validating the Sensitivity of High-Resolution Melting Analysis for JAK2 V617F Mutation in the Clinical Setting.

Authors:  Chien-Yu Lin; Cheng-Mao Ho; Gevorg Tamamyan; Shu-Fen Yang; Ching-Tien Peng; Jan-Gowth Chang
Journal:  J Clin Lab Anal       Date:  2016-05-12       Impact factor: 2.352

2.  Clinical and biological characterization of patients with low (0.1-2%) JAK2V617F allele burden at diagnosis.

Authors:  Eric Lippert; Olivier Mansier; Marina Migeon; Barbara Denys; Asa Nilsson; Carolina Rosmond; Laurence Lodé; Valérie Ugo; Axelle Lascaux; Beatriz Bellosillo; Joaquin Martinez-Lopez; Dina Naguib; Nathalie Gachard; Nicolas Maroc; Sylvie Hermouet
Journal:  Haematologica       Date:  2014-05-16       Impact factor: 9.941

3.  Summary and Review of the Abstracts on Philadelphia-Negative Myeloproliferative Neoplasms Presented at Haematocon 2017.

Authors:  Tathagata Chatterjee; Ankur Ahuja
Journal:  Indian J Hematol Blood Transfus       Date:  2018-02-03       Impact factor: 0.900

4.  A highly sensitive quantitative real-time PCR assay for determination of mutant JAK2 exon 12 allele burden.

Authors:  Lasse Kjær; Maj Westman; Caroline Hasselbalch Riley; Estrid Høgdall; Ole Weis Bjerrum; Hans Hasselbalch
Journal:  PLoS One       Date:  2012-03-05       Impact factor: 3.240

5.  High-resolution melting (HRM) re-analysis of a polyposis patients cohort reveals previously undetected heterozygous and mosaic APC gene mutations.

Authors:  Astrid A Out; Ivonne J H M van Minderhout; Nienke van der Stoep; Lysette S R van Bommel; Irma Kluijt; Cora Aalfs; Marsha Voorendt; Rolf H A M Vossen; Maartje Nielsen; Hans F A Vasen; Hans Morreau; Peter Devilee; Carli M J Tops; Frederik J Hes
Journal:  Fam Cancer       Date:  2015-06       Impact factor: 2.375

Review 6.  Monitoring Minimal Residual Disease in the Myeloproliferative Neoplasms: Current Applications and Emerging Approaches.

Authors:  Karl Haslam; Stephen E Langabeer
Journal:  Biomed Res Int       Date:  2016-10-20       Impact factor: 3.411

7.  Analysis of the reannealing- instead of melting-curve in the detection of JAK2 V617F mutation by HRM method.

Authors:  Alireza Moradabadi; Ahmad Fatemi; Ali Noroozi-Aghideh
Journal:  J Blood Med       Date:  2019-07-22

8.  Diagnosis of exon 12-positive polycythemia vera rescued by NGS.

Authors:  Antoine Geay; Bernard Aral; Valentin Bourgeois; Pauline Martin; Fabrice Airaud; Céline Garrec; Stéphane Bézieau; Betty Gardie; François Girodon
Journal:  Clin Case Rep       Date:  2020-03-21

9.  Investigation of genetic disturbances in oxygen sensing and erythropoietin signaling pathways in cases of idiopathic erythrocytosis.

Authors:  Carla Luana Dinardo; Paulo Caleb Junior Lima Santos; Isolmar Tadeu Schettert; Renata Alonso Gadi Soares; Jose Eduardo Krieger; Alexandre Costa Pereira
Journal:  Genet Res Int       Date:  2013-12-02

10.  Calreticulin Mutations in Myeloproliferative Neoplasms: Comparison of Three Diagnostic Methods.

Authors:  Ji-Hye Park; Margaux Sevin; Selim Ramla; Aurélie Truffot; Tiffany Verrier; Dominique Bouchot; Martine Courtois; Mathilde Bas; Sonia Benali; François Bailly; Bernardine Favre; Julien Guy; Laurent Martin; Marc Maynadié; Serge Carillo; François Girodon
Journal:  PLoS One       Date:  2015-10-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.